ID: ALA2440712

Max Phase: Preclinical

Molecular Formula: C21H34N4O3S

Molecular Weight: 422.60

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCNC(=O)Nc1cc(/C=C/C(=O)NO)ccc1SCCN(CC)CC

Standard InChI:  InChI=1S/C21H34N4O3S/c1-4-7-8-13-22-21(27)23-18-16-17(10-12-20(26)24-28)9-11-19(18)29-15-14-25(5-2)6-3/h9-12,16,28H,4-8,13-15H2,1-3H3,(H,24,26)(H2,22,23,27)/b12-10+

Standard InChI Key:  HWENGHCULNSUQK-ZRDIBKRKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 422.60

Molecular Weight (Monoisotopic): 422.2352

AlogP: 3.95

#Rotatable Bonds: 13

Polar Surface Area: 93.70

Molecular Species: BASE

HBA: 5

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.70

CX Basic pKa: 9.02

CX LogP: 2.83

CX LogD: 1.56

Aromatic Rings: 1

Heavy Atoms: 29

QED Weighted: 0.13

Np Likeness Score: -1.14

References

1. Ning C, Bi Y, He Y, Huang W, Liu L, Li Y, Zhang S, Liu X, Yu N..  (2013)  Design, synthesis and biological evaluation of di-substituted cinnamic hydroxamic acids bearing urea/thiourea unit as potent histone deacetylase inhibitors.,  23  (23): [PMID:24119555] [10.1016/j.bmcl.2013.09.051]

2.  (2014)  Histone deacetylase inhibitors, process for preparation and uses thereof, 

Source

Source(2):

• Scientific Literature
• BindingDB Database